Symbols / REVB $1.22 -2.02%
REVB Chart
About
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.52M |
| Enterprise Value | -5.40M | Income | -14.87M | Sales | — |
| Book/sh | 5.59 | Cash/sh | 2.89 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -0.37 | PEG | — |
| P/S | — | P/B | 0.22 | P/C | — |
| EV/EBITDA | 0.60 | EV/Sales | — | Quick Ratio | 5.38 |
| Current Ratio | 5.41 | Debt/Eq | 8.43 | LT Debt/Eq | — |
| EPS (ttm) | -23.95 | EPS next Y | -3.29 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-07 | ROA | -62.28% |
| ROE | -131.38% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 3.72M |
| Shs Float | 3.27M | Short Float | 0.37% | Short Ratio | 0.04 |
| Short Interest | — | 52W High | 44.77 | 52W Low | 1.19 |
| Beta | -0.13 | Avg Volume | 674.41K | Volume | 39.99K |
| Target Price | $43.25 | Recom | None | Prev Close | $1.24 |
| Price | $1.22 | Change | -2.02% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$43.25
Mean price target
2. Current target
$1.22
Latest analyst target
3. DCF / Fair value
$-24.06
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.22
Low
$22.50
High
$64.00
Mean
$43.25
- Revelation Biosciences to combine 4 shares into 1 for Nasdaq bid - Stock Titan Mon, 26 Jan 2026 08
- REVB Stock Drops 10% After Company Announces Third Reverse Split In A Year - Stocktwits Wed, 28 Jan 2026 08
- Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours? - Benzinga Fri, 23 Jan 2026 08
- Revelation Biosciences (REVB) stock ticks up premarket after FDA lays out Gemini trial path - TechStock² Fri, 23 Jan 2026 08
- Kidney drug Gemini advances at Revelation, cash runway into 2027 - Stock Titan hu, 26 Feb 2026 08
- REVB stock touches 52-week low at $0.86 amid sharp annual decline - Investing.com hu, 29 May 2025 07
- Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering - Yahoo Finance hu, 29 May 2025 07
- Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025 - Business Wire ue, 01 Jul 2025 07
- Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds - Idaho Statesman Fri, 23 Jan 2026 08
- Revelation Biosciences trades new 5-year warrants for $11M cash - Stock Titan Fri, 23 Jan 2026 08
- Revelation Biosciences to implement 1-for-4 reverse stock split By Investing.com - Investing.com Nigeria Mon, 26 Jan 2026 08
- Revelation Biosciences Stock Slides 17% After Company Reports 3 Severe Adverse Events In Early Stage Trial Of Inflammation Drug - Stocktwits ue, 09 Sep 2025 07
- Why Revelation Biosciences Inc. (REVB) Went Down On Thursday? - Yahoo Finance hu, 10 Apr 2025 07
- Biotech recruits new employee with 90,000 stock units over 2 years - Stock Titan Mon, 12 Jan 2026 08
- New kidney study to show how Gemini may help acute injury patients - Stock Titan Wed, 14 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 41981 | 37783 | — | Stock Award(Grant) at price 0.90 per share. | CHAWLA LAKHMIR S | Director | — | 2026-01-08 00:00:00 | D |
| 1 | 41981 | 37783 | — | Stock Award(Grant) at price 0.90 per share. | CARVER JENNIFER A | Director | — | 2026-01-08 00:00:00 | D |
| 2 | 532829 | 479546 | — | Stock Award(Grant) at price 0.90 per share. | ROLKE JAMES M | Chief Executive Officer | — | 2026-01-08 00:00:00 | D |
| 3 | 78145 | 70330 | — | Stock Award(Grant) at price 0.90 per share. | ZYGMONT CHESTER STANLEY III | Chief Financial Officer | — | 2026-01-08 00:00:00 | I |
| 4 | 41981 | 37783 | — | Stock Award(Grant) at price 0.90 per share. | ROPER JESS | Director | — | 2026-01-08 00:00:00 | D |
| 5 | 15625 | 20000 | — | Stock Award(Grant) at price 1.28 per share. | CHAWLA LAKHMIR S | Director | — | 2025-10-29 00:00:00 | D |
| 6 | 15625 | 20000 | — | Stock Award(Grant) at price 1.28 per share. | CARVER JENNIFER A | Director | — | 2025-10-29 00:00:00 | D |
| 7 | 390614 | 499986 | — | Stock Award(Grant) at price 1.28 per share. | ROLKE JAMES M | Chief Executive Officer | — | 2025-10-29 00:00:00 | D |
| 8 | 390614 | 499986 | — | Stock Award(Grant) at price 1.28 per share. | ZYGMONT CHESTER STANLEY III | Chief Financial Officer | — | 2025-10-29 00:00:00 | I |
| 9 | 15625 | 20000 | — | Stock Award(Grant) at price 1.28 per share. | ROPER JESS | Director | — | 2025-10-29 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -9.05M | -8.03M | -16.96M | -10.84M |
| TotalUnusualItems | 2.16K | 81.44K | 8.33M | |
| TotalUnusualItemsExcludingGoodwill | 2.16K | 81.44K | 8.33M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -8.91M | -15.04M | -120.25K | -10.83M |
| ReconciledDepreciation | 27.06K | 27.92K | 25.05K | 25.05K |
| EBITDA | -9.04M | -7.95M | -8.63M | -10.84M |
| EBIT | -9.07M | -7.98M | -8.66M | -10.86M |
| NormalizedIncome | -8.92M | -15.12M | -8.45M | -10.83M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -8.91M | -15.04M | -120.25K | -10.83M |
| TotalExpenses | 9.07M | 7.98M | 8.66M | 10.86M |
| TotalOperatingIncomeAsReported | -9.07M | -7.98M | -8.66M | -10.86M |
| DilutedAverageShares | 620.78K | 14.29K | 1.19K | 118.00 |
| BasicAverageShares | 620.78K | 14.29K | 1.19K | 118.00 |
| DilutedEPS | -23.95 | -1.05K | -101.28 | -91.78K |
| BasicEPS | -23.95 | -1.05K | -101.28 | -91.78K |
| DilutedNIAvailtoComStockholders | -14.87M | -15.04M | -120.25K | -10.83M |
| NetIncomeCommonStockholders | -14.87M | -15.04M | -120.25K | -10.83M |
| OtherunderPreferredStockDividend | 5.95M | 0.00 | ||
| NetIncome | -8.91M | -15.04M | -120.25K | -10.83M |
| NetIncomeIncludingNoncontrollingInterests | -8.91M | -15.04M | -120.25K | -10.83M |
| NetIncomeContinuousOperations | -8.91M | -15.04M | -120.25K | -10.83M |
| PretaxIncome | -8.91M | -15.04M | -120.25K | -10.83M |
| OtherIncomeExpense | 157.16K | -7.06M | 8.54M | 34.96K |
| OtherNonOperatingIncomeExpenses | 155.01K | -7.14M | 207.47K | 34.96K |
| GainOnSaleOfSecurity | 2.16K | 81.44K | 8.33M | |
| OperatingIncome | -9.07M | -7.98M | -8.66M | -10.86M |
| OperatingExpense | 9.07M | 7.98M | 8.66M | 10.86M |
| ResearchAndDevelopment | 4.06M | 3.55M | 4.15M | 5.38M |
| SellingGeneralAndAdministration | 5.01M | 4.43M | 4.51M | 5.49M |
| GeneralAndAdministrativeExpense | 5.01M | 4.43M | 4.51M | 5.49M |
| OtherGandA | 1.96M | 1.66M | 2.24M | 3.61M |
| SalariesAndWages | 3.05M | 2.77M | 2.27M | 1.87M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 1.58M | 43.52K | 1.38K | 118.00 |
| ShareIssued | 1.58M | 43.52K | 1.38K | 118.00 |
| TotalDebt | 746.78K | 0.00 | 0.00 | 16.75K |
| TangibleBookValue | 8.86M | 4.71M | 6.65M | 1.05M |
| InvestedCapital | 8.86M | 4.71M | 6.65M | 1.05M |
| WorkingCapital | 8.81M | 4.65M | 6.58M | 962.32K |
| NetTangibleAssets | 8.86M | 4.71M | 6.65M | 1.05M |
| CapitalLeaseObligations | 746.78K | 0.00 | 0.00 | 16.75K |
| CommonStockEquity | 8.86M | 4.71M | 6.65M | 1.05M |
| PreferredStockEquity | 7.48M | |||
| TotalCapitalization | 8.86M | 4.71M | 6.65M | 1.05M |
| TotalEquityGrossMinorityInterest | 8.86M | 4.71M | 6.65M | 1.05M |
| StockholdersEquity | 8.86M | 4.71M | 6.65M | 1.05M |
| RetainedEarnings | -49.42M | -40.51M | -25.47M | -25.35M |
| AdditionalPaidInCapital | 58.28M | 45.21M | 32.11M | 26.40M |
| CapitalStock | 1.58K | 44.00 | 16.00 | 77.00 |
| CommonStock | 1.58K | 44.00 | 16.00 | 77.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 2.72M | 1.91M | 5.56M | 4.45M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 723.77K | 0.00 | 0.00 | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 723.77K | 0.00 | ||
| LongTermCapitalLeaseObligation | 723.77K | 0.00 | ||
| CurrentLiabilities | 2.00M | 1.91M | 5.56M | 4.45M |
| OtherCurrentLiabilities | 2.25K | 141.28K | ||
| CurrentDeferredLiabilities | 0.00 | 2.91M | 2.91M | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 23.01K | 16.75K | ||
| CurrentCapitalLeaseObligation | 23.01K | 0.00 | 0.00 | 16.75K |
| PayablesAndAccruedExpenses | 1.98M | 1.91M | 2.51M | 1.54M |
| CurrentAccruedExpenses | 1.40M | 1.13M | 1.15M | 985.50K |
| Payables | 577.50K | 783.62K | 1.36M | 554.21K |
| AccountsPayable | 577.50K | 783.62K | 1.36M | 554.21K |
| TotalAssets | 11.58M | 6.62M | 12.21M | 5.50M |
| TotalNonCurrentAssets | 771.30K | 56.33K | 65.08K | 90.13K |
| OtherNonCurrentAssets | 30.94K | |||
| NetPPE | 740.36K | 56.33K | 65.08K | 90.13K |
| AccumulatedDepreciation | -98.99K | -94.80K | -66.88K | -41.83K |
| GrossPPE | 839.34K | 151.13K | 131.96K | 131.96K |
| OtherProperties | 839.34K | 151.13K | 131.96K | 131.96K |
| CurrentAssets | 10.81M | 6.57M | 12.15M | 5.41M |
| OtherCurrentAssets | 33.95K | 49.50K | 29.48K | 73.13K |
| CurrentDeferredAssets | 0.00 | 71.13K | 87.17K | 0.00 |
| PrepaidAssets | 77.35K | 17.20K | 55.22K | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 10.70M | 6.50M | 11.99M | 5.25M |
| CashAndCashEquivalents | 10.70M | 6.50M | 11.99M | 5.25M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -8.27M | -18.34M | -7.29M | -11.22M |
| RepurchaseOfCapitalStock | 0.00 | -5.00K | ||
| RepaymentOfDebt | 0.00 | -3.30M | 0.00 | |
| IssuanceOfDebt | 0.00 | 2.50M | 0.00 | |
| IssuanceOfCapitalStock | 3.39M | 5.42M | 14.03M | 4.46M |
| CapitalExpenditure | -19.17K | -131.96K | ||
| EndCashPosition | 10.70M | 6.50M | 11.99M | 5.25M |
| BeginningCashPosition | 6.50M | 11.99M | 5.25M | 1.27M |
| ChangesInCash | 4.20M | -5.49M | 6.74M | 3.98M |
| FinancingCashFlow | 12.47M | 12.85M | 14.03M | 15.20M |
| CashFlowFromContinuingFinancingActivities | 12.47M | 12.85M | 14.03M | 15.20M |
| NetOtherFinancingCharges | 11.53M | |||
| ProceedsFromStockOptionExercised | 9.08M | 7.43M | 34.00 | 5.09K |
| NetPreferredStockIssuance | 0.00 | -5.00K | 5.00K | 7.40M |
| PreferredStockPayments | 0.00 | -5.00K | ||
| PreferredStockIssuance | 5.00K | 7.40M | ||
| NetCommonStockIssuance | 3.39M | 5.42M | 14.03M | 4.45M |
| CommonStockIssuance | 3.39M | 5.42M | 14.03M | 4.45M |
| NetIssuancePaymentsOfDebt | 0.00 | -796.88K | 0.00 | |
| NetShortTermDebtIssuance | 0.00 | -796.88K | 0.00 | |
| ShortTermDebtPayments | 0.00 | -3.30M | 0.00 | |
| ShortTermDebtIssuance | 0.00 | 2.50M | 0.00 | |
| InvestingCashFlow | 0.00 | -19.17K | 0.00 | 0.00 |
| CashFlowFromContinuingInvestingActivities | 0.00 | -19.17K | 0.00 | 0.00 |
| NetPPEPurchaseAndSale | 0.00 | -19.17K | 0.00 | 0.00 |
| PurchaseOfPPE | 0.00 | -19.17K | 0.00 | 0.00 |
| OperatingCashFlow | -8.27M | -18.32M | -7.29M | -11.22M |
| CashFlowFromContinuingOperatingActivities | -8.27M | -18.32M | -7.29M | -11.22M |
| ChangeInWorkingCapital | -6.04K | -3.42M | 982.13K | -730.97K |
| ChangeInOtherWorkingCapital | 71.13K | 82.07K | -61.15K | |
| ChangeInOtherCurrentLiabilities | 5.87K | 0.00 | 0.00 | -16.75K |
| ChangeInOtherCurrentAssets | -30.94K | 0.00 | ||
| ChangeInPayablesAndAccruedExpense | 63.64K | -3.51M | 911.62K | -1.22M |
| ChangeInAccruedExpense | 269.76K | -2.94M | 161.96K | -556.07K |
| ChangeInInterestPayable | 0.00 | 36.92K | 0.00 | |
| ChangeInPayable | -206.12K | -576.28K | 749.66K | -666.04K |
| ChangeInAccountPayable | -206.12K | -576.28K | 749.66K | -666.04K |
| ChangeInPrepaidAssets | -44.60K | 17.99K | -11.56K | 569.04K |
| OtherNonCashItems | 18.63K | 25.00K | 14.96K | 52.38K |
| StockBasedCompensation | 595.37K | 168.85K | 155.72K | 301.12K |
| DepreciationAmortizationDepletion | 27.06K | 27.92K | 25.05K | 25.05K |
| DepreciationAndAmortization | 27.06K | 27.92K | 25.05K | 25.05K |
| Depreciation | 27.06K | 27.92K | 25.05K | 25.05K |
| OperatingGainsLosses | 9.05K | -81.44K | -8.33M | |
| GainLossOnInvestmentSecurities | -2.16K | -81.44K | -8.33M | |
| GainLossOnSaleOfPPE | 11.21K | 0.00 | ||
| NetIncomeFromContinuingOperations | -8.91M | -15.04M | -120.25K | -10.83M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for REVB
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|